Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
QTREX Quantum (Nasdaq: QTEX) received an approximately $1 million grant from the Israel Innovation Authority to develop a native RF dielectric material for superconducting quantum computing connectivity.
The program focuses on high-density, low-loss RF signal routing inside cryogenic environments, targeting connectivity bottlenecks as quantum processors scale.
QTREX Quantum (Nasdaq:IINN) will present functional AME-based monolithic connectivity components for quantum computing systems at Quantum.Tech World 2026 in Boston on June 25–26, 2026.
The company will hold private, invitation-only meetings showcasing components addressing cryogenic interconnect challenges in superconducting quantum systems.
QTREX Quantum (Nasdaq: QTEX) received a purchase order from a U.S.-based Fortune 500 multinational for an Additively Manufactured Electronics (AME) system and related materials. The system, destined for a non-U.S. site, adds a global enterprise to QTREX’s AME customer base.
The AME platform is designed to create intricate structures with advanced materials in a single workflow, targeting complexity limits of conventional manufacturing and quantum connectivity. The order is expected to contribute to upcoming financial results and, together with recent orders, supports a commercial revenue base that, according to QTREX, already exceeds the most recently reported annual revenues of certain publicly traded quantum computing companies.
QTREX Quantum (Nasdaq: QTEX) priced a $10 million private placement of 6,666,667 ordinary shares (or equivalents) with a new institutional investor. Closing is expected around June 1, 2026, with net proceeds earmarked for working capital, corporate purposes, commercialization of AME-based cryogenic interconnects, and R&D.
QTREX Quantum (Nasdaq:IINN) is in advanced talks with a top-five global quantum computing company on a potential strategic collaboration. Both sides are running a joint technical evaluation of QTREX’s AME-based cryogenic interconnects within the partner’s refrigerator architecture.
If a definitive agreement is signed, the partner could adopt QTREX’s platform as its foundational cryogenic interconnect technology, embedding QTREX as a critical supplier across its future quantum hardware roadmap and aligning QTREX’s revenue prospects with the partner’s global deployment growth.
Inspira Technologies (Nasdaq: IINN) will change its corporate name to QTREX Quantum and begin trading under the new Nasdaq ticker QTEX on May 20, 2026. Warrants will trade as QTEXW. No shareholder action is required.
The new name highlights a strategic focus on its Additively Manufactured Electronics (AME) platform for advanced manufacturing, high‑performance electronics and quantum connectivity, targeting quantum computing connectivity inside dilution cryostats.
Inspira Technologies (Nasdaq:IINN) announced a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems, following a multi-patient hospital evaluation of more than 30 cases.
The order will be fulfilled immediately and serves as a key reference within Inspira’s ongoing strategic process for ART100 and related assets.
Inspira Technologies (NASDAQ:IINN) outlined a three-track plan focused on an AME electronics platform, quantum computing connectivity and monetization of its medical business. The company acquired Nano Dimension’s AME platform, signed a joint development deal with Qarakal Quantum, and reported over $1 million in recent AME transactions.
Management is reducing the legacy medical burn rate and exploring sales of medical assets by Q3 2026 to generate non-dilutive capital. FDA-cleared ART100 has treated 40+ patients, and HYLA is being prepared for FDA submission. Shareholders approved a name change to QTREX Quantum.
Inspira (Nasdaq: IINN) secured a $596,000 purchase order for an Additively Manufactured Electronics (AME) system from a leading Irish technological research university on May 1, 2026.
The order includes a 40% non-refundable upfront payment already received, with the balance due on delivery. Inspira expects delivery in the coming weeks, training for research teams, and recurring revenue from proprietary consumables, wear parts, and annual service fees tied to system usage. The installation is intended as a reference site for further academic and commercial engagements across Europe.
Inspira (Nasdaq: IINN) signed a Joint Development Agreement with Qarakal Quantum to test Inspira’s QTREX additively manufactured electronics in superconducting, cryogenic environments. The multi‑phase program will supply 3D‑printed conductive and insulating structures for milli‑Kelvin testing, with metrics, scope, timelines, and resource commitments to be finalized.
The collaboration targets high‑density routing, integrated transitions, embedded shielding, rigid‑flex monolithics, and more compact interconnect geometries to address cryogenic signal‑connectivity scaling challenges in superconducting quantum systems.